We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+17.08%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$13.4B
AUM Growth
+$5.98B
(+81%)
Cap. Flow
+$4.58B
Cap. Flow
% of AUM
34.18%
Top 10 Holdings %
Top 10 Hldgs %
24.57%
Holding
3,476
New
1,044
Increased
804
Reduced
979
Closed
616
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.46B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$437M |
| 3 |
Apple
AAPL
|
+$199M |
| 4 |
Amazon
AMZN
|
+$185M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$142M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$51.4M |
| 2 |
Lowe's Companies
LOW
|
+$45.3M |
| 3 |
CVS Health
CVS
|
+$37.3M |
| 4 |
Eli Lilly
LLY
|
+$32.7M |
| 5 |
Southern Company
SO
|
+$30.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.47% |
| 2 | Consumer Discretionary | 11.59% |
| 3 | Healthcare | 8.66% |
| 4 | Financials | 6.8% |
| 5 | Industrials | 5.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRNS
2001
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $394K | ﹤0.01% |
32,296
+19,822
| +159% | +$276K |
|
|
ESPR
2002
DELISTED
Esperion Therapeutics
ESPR
| $393K | ﹤0.01% |
+15,109
| New | +$453K |
|
|
EPZM
2003
DELISTED
Epizyme, Inc
EPZM
| $393K | ﹤0.01% |
36,159
-44,212
| -55% | -$545K |
|
2004
Pool Corp
POOL
$6.7B
| $392K | ﹤0.01% |
1,052
-18,700
| -95% | -$6.52M |
|
2005
Aramark
ARMK
$15B
| $391K | ﹤0.01% |
14,056
-846,913
| -98% | -$20.3M |
|
2006
Pathward Financial
CASH
$1.81B
| $391K | ﹤0.01% |
+10,692
| New | +$326K |
|
2007
CALL
Dominion Energy
D
$62.5B
| $391K | ﹤0.01% |
+5,200
| New | +$413K |
|
2008
e.l.f. Beauty
ELF
$4.56B
| $391K | ﹤0.01% |
15,513
-1,172
| -7% | -$25.2K |
|
|
GBIO
2009
DELISTED
Generation Bio
GBIO
| $391K | ﹤0.01% |
+1,378
| New | +$442K |
|
|
JHG
2010
DELISTED
Janus Henderson
JHG
| $390K | ﹤0.01% |
+12,005
| New | +$343K |
|
|
EGRX
2011
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $390K | ﹤0.01% |
8,381
-4,953
| -37% | -$232K |
|
2012
CALL
Walmart Inc
WMT
$871B
| $389K | ﹤0.01% |
8,100
-3,600
| -31% | -$175K |
|
|
2013
PUT
Walmart Inc
WMT
$871B
| $389K | ﹤0.01% |
8,100
-3,600
| -31% | -$175K |
|
2014
BeyondSpring
BYSI
$46.1M
| $388K | ﹤0.01% |
+31,802
| New | +$418K |
|
2015
Neurocrine Biosciences
NBIX
$17.7B
| $388K | ﹤0.01% |
4,044
-9,795
| -71% | -$946K |
|
2016
Nomad Foods
NOMD
$1.64B
| $388K | ﹤0.01% |
+15,273
| New | +$378K |
|
|
USX
2017
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $388K | ﹤0.01% |
56,795
-40,209
| -41% | -$314K |
|
|
SMED
2018
DELISTED
Sharps Compliance Corp
SMED
| $388K | ﹤0.01% |
41,070
-1,696
| -4% | -$13K |
|
2019
Coherus Oncology
CHRS
$217M
| $387K | ﹤0.01% |
+22,254
| New | +$396K |
|
|
CSII
2020
DELISTED
Cardiovascular Systems, Inc.
CSII
| $387K | ﹤0.01% |
8,845
-17,022
| -66% | -$641K |
|
2021
Axogen
AXGN
$2.1B
| $386K | ﹤0.01% |
21,551
+3,596
| +20% | +$52.8K |
|
2022
Codexis
CDXS
$135M
| $386K | ﹤0.01% |
17,680
-31,614
| -64% | -$520K |
|
2023
RE/MAX Holdings
RMAX
$200M
| $385K | ﹤0.01% |
+10,587
| New | +$360K |
|
2024
Emcor
EME
$33.1B
| $384K | ﹤0.01% |
4,200
-16,737
| -80% | -$1.34M |
|
2025
Limbach Holdings
LMB
$867M
| $384K | ﹤0.01% |
+31,155
| New | +$334K |
|
Similar funds
Squarepoint's Q4 2020 Portfolio in Review
As of Q4 2020, Squarepoint held 3,476 positions worth $13.4B, up 81% from $7.42B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Squarepoint deployed $4.58B of net new capital in Q4 2020, opening 1,044 new positions and adding to 804 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 4,102,602 shares worth $1.54B.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Intuit, an estimated $51.4M trimmed.
- Squarepoint's largest Q4 2020 buy was iShares Core S&P 500 ETF: 4,102,602 shares worth $1.54B.
- Squarepoint added most to State Street SPDR S&P 500 ETF Trust in Q4 2020, an estimated $437M increase.
- Squarepoint's biggest Q4 2020 reduction was Intuit, cutting an estimated $51.4M.
- Squarepoint fully exited iShares Biotechnology ETF in Q4 2020, selling an estimated $29.3M.
- Squarepoint's ten largest holdings make up 25% of its $13.4B portfolio in Q4 2020.
- Squarepoint opened 1,044 new positions and closed 616 in Q4 2020.
- Squarepoint's portfolio value rose 81% quarter-over-quarter to $13.4B.
Based on Squarepoint's 13F filing for Q4 2020, filed 16 Feb 2021.